Inhibition of Colon Carcinogenesis by 2-Methoxy-5-Amino-N-Hydroxybenzamide, a Novel Derivative of Mesalamine

Gastroenterology

Volumn 138, Issue 1, 2010, Pages 221-230

  Stolfi, Carmine ^a   Sarra, Massimiliano ^a   Caruso, Roberta ^a   Fantini, Massimo Claudio ^a   Fina, Daniele ^a   Pellegrini, Roberto ^a   Palmieri, Giampiero ^a   Macdonald, Thomas T ^b   Pallone, Francesco ^a   Monteleone, Giovanni ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXY 5 AMINO N HYDROXYBENZAMIDE; ACTIVATING TRANSCRIPTION FACTOR 4; ANTINEOPLASTIC AGENT; AZOXYMETHANE; CYCLIN D1; CYCLIN DEPENDENT KINASE; DEXTRAN SULFATE; EUKARYOTIC TRANSLATION INITIATION FACTOR 2 ALPHA KINASE 3; INITIATION FACTOR 2; INITIATION FACTOR 2ALPHA; MESALAZINE; MESSENGER RNA; PROTEIN KINASE R; UNCLASSIFIED DRUG; X BOX BINDING PROTEIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PREVENTION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; COLITIS; COLON CARCINOGENESIS; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; XENOGRAFT;

EID: 72249112919     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2009.08.062     Document Type: Article

References (32)

1. Ferlay J., Autier P., Boniol M., et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18 (2007) 581-592
2. Huls G., Koornstra J.J., and Kleibeuker J.H. Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas. Lancet 362 (2003) 230-232
3. Steinbach G., Lynch P.M., Phillips R.K., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342 (2000) 1946-1952
4. Bresalier R.S., Sandler R.S., Quan H., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 (2005) 1092-1102
5. Eaden J.A., Abrams K.R., and Mayberry J.F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48 (2001) 526-535
6. Velayos F.S., Terdiman J.P., and Walsh J.M. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 100 (2005) 1345-1353
7. Rubin D.T., LoSavio A., Yadron N., et al. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol 4 (2006) 1346-1350
8. Rousseaux C., Lefebvre B., Dubuquoy L., et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med 201 (2005) 1205-1215
9. Monteleone G., Franchi L., Fina D., et al. Silencing of SH-PTP2 defines a crucial role in the inactivation of epidermal growth factor receptor by 5-aminosalicylic acid in colon cancer cells. Cell Death Differ 13 (2006) 202-211
10. Stolfi C., Fina D., Caruso R., et al. Mesalazine negatively regulates CDC25A protein expression and promotes accumulation of colon cancer cells in S phase. Carcinogenesis 29 (2008) 1258-1266
11. Frieri G., Pimpo M.T., Palumbo G.C., et al. Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment. Aliment Pharmacol Ther 13 (1999) 1413-1417
12. Myers B., Evans D.N., Rhodes J., et al. Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut 28 (1987) 196-200
13. Bondesen S., Hegnhoj J., Larsen F., et al. Pharmacokinetics of 5-aminosalicylic acid in man following administration of intravenous bolus and per os slow-release formulation. Dig Dis Sci 36 (1991) 1735-1740
14. Terdiman J.P., Steinbuch M., Blumentals W.A., et al. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis 13 (2007) 367-371
15. Ullman T., Croog V., Harpaz N., et al. Progression to colorectal neoplasia in ulcerative colitis: effect of mesalamine. Clin Gastroenterol Hepatol 6 (2008) 1225-1230 quiz 1177
16. Stolfi C., Fina D., Caruso R., et al. Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. Biochem Pharmacol 75 (2008) 668-676
17. Shapiro G.I. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24 (2006) 1770-1783
18. Brewer J.W., Hendershot L.M., Sherr C.J., et al. Mammalian unfolded protein response inhibits cyclin D1 translation and cell-cycle progression. Proc Natl Acad Sci U S A 96 (1999) 8505-8510
19. Schroder M. Endoplasmic reticulum stress responses. Cell Mol Life Sci 65 (2008) 862-894
20. Kim I., Xu W., and Reed J.C. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov 7 (2008) 1013-1030
21. Ma Y., and Hendershot L.M. The role of the unfolded protein response in tumour development: friend or foe?. Nat Rev Cancer 4 (2004) 966-977
22. Ranganathan A.C., Ojha S., Kourtidis A., et al. Dual function of pancreatic endoplasmic reticulum kinase in tumor cell growth arrest and survival. Cancer Res 68 (2008) 3260-3268
23. Gomez E., Powell M.L., Bevington A., et al. A decrease in cellular energy status stimulates PERK-dependent eIF2alpha phosphorylation and regulates protein synthesis in pancreatic beta-cells. Biochem J 410 (2008) 485-493
24. Xu C., Bailly-Maitre B., and Reed J.C. Endoplasmic reticulum stress: cell life and death decisions. J Clin Invest 115 (2005) 2656-2664
25. Zakeri Z., and Lockshin R.A. Cell death: history and future. Adv Exp Med Biol 615 (2008) 1-11
26. Ikeda I., Tomimoto A., Wada K., et al. 5-aminosalicylic acid given in the remission stage of colitis suppresses colitis-associated cancer in a mouse colitis model. Clin Cancer Res 13 (2007) 6527-6531
27. Hamanaka R.B., Bennett B.S., Cullinan S.B., et al. PERK and GCN2 contribute to eIF2alpha phosphorylation and cell cycle arrest after activation of the unfolded protein response pathway. Mol Biol Cell 16 (2005) 5493-5501
28. Shuda M., Kondoh N., Imazeki N., et al. Activation of the ATF6, XBP1 and grp78 genes in human hepatocellular carcinoma: a possible involvement of the ER stress pathway in hepatocarcinogenesis. J Hepatol 38 (2003) 605-614
29. Fujimoto T., Onda M., Nagai H., et al. Upregulation and overexpression of human X-box binding protein 1 (hXBP-1) gene in primary breast cancers. Breast Cancer 10 (2003) 301-306
30. Lee A.H., Iwakoshi N.N., Anderson K.C., et al. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci U S A 100 (2003) 9946-9951
31. Nawrocki S.T., Carew J.S., Dunner Jr. K., et al. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res 65 (2005) 11510-11519
32. Nawrocki S.T., Carew J.S., Pino M.S., et al. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res 65 (2005) 11658-11666